All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Merck to Discontinue KEYNOTE-867 and KEYNOTE-630 Trials of Pembrolizumab in NSCLC, CSCC

August 29th 2024

The phase 3 KEYNOTE-867 and KEYNOTE-630 trials evaluating pembrolizumab in NSCLC and CSCC, respectively, have been discontinued by Merck.

ADT Plus Darolutamide Is Associated With Lower Rates of PSA Progression in nmCRPC

August 29th 2024

Alicia Morgans, MD, MPH, discusses the use of ADT in combination with darolutamide or placebo in nonmetastatic castration-resistant prostate cancer.

Shortened Trastuzumab Administration Does Not Improve DFS in ERBB2+ Breast Cancer

August 29th 2024

Adjuvant trastuzumab plus concurrent chemotherapy led to inferior DFS outcomes when administered for 9 weeks vs 1 year in ERBB2-positive breast cancer.

Oxaliplatin Plus Fluoropyrimidine/Bevacizumab Does Not Improve Survival in Older Patients With mCRC

August 29th 2024

Oxaliplatin plus fluoropyrimidine and bevacizumab confers little therapeutic benefit to older patients with metastatic colorectal cancer.

Charlson Comorbidities Associated With Lower Likelihood of CR in Epithelial Ovarian Cancer

August 28th 2024

Kimberly Cannavale, MPH, discusses a study of the association between Charlson comorbidity index and complete remission in patients with ovarian cancer.

Novel Targets Facilitate Treatment Advances and Spur Further Questions in Endometrial Cancer

August 28th 2024

Ritu Salani, MD, discusses the development of ADCs, the potential role of selinexor, and the use of PARP inhibitors across endometrial cancer subsets.

Dual Checkpoint Blockade Usurps PD-1 Monotherapy as Gold Standard in Unresectable Melanoma

August 28th 2024

Ankit Mangla, MD, expands on key survival data from the phase 2/3 RELATIVITY-047 trial in previously untreated, unresectable, or metastatic melanoma.

FDA Grants Priority Review to Mirdametinib for NF1-Associated Plexiform Neurofibromas

August 28th 2024

Priority review was granted to the NDA seeking approval of mirdametinib in patients with neurofibromatosis type 1–associated plexiform neurofibromas.

NDA Submitted to FDA for TLX101-CDx in Progressive/Recurrent Glioma

August 28th 2024

An NDA has been submitted to the FDA for TLX101-CDx for the characterization of progressive or recurrent glioma in adult and pediatric patients.

Enfortumab Vedotin Plus Pembrolizumab Approved in Europe for Metastatic Urothelial Cancer

August 28th 2024

The European Commission granted marketing authorization to frontline enfortumab vedotin plus pembrolizumab for unresectable/metastatic urothelial cancer.

Fox Chase Cancer Center Welcomes Dr. Michael Seidman

August 28th 2024

Michael Seidman, MD, has joined Fox Chase Cancer Center as a Professor in the Department of Hematology/Oncology.

Dissemination vs Misinformation: Social Media’s Role in the Evolution of Cancer Care

August 28th 2024

As the dissemination of information in oncology is spread using social media platforms, the potential for misinformation remains a key hurdle.

Nailing it Down: What Will AI’s Role Be in Cancer Care?

August 28th 2024

Krishnansu S. Tewari, MD, details the current and possible future applications of AI in cancer care as well as the limitations of the technology.

CARACO Data Add to Evidence Supporting Omission of Lymphadenectomy in Advanced Ovarian Cancer Without Suspicious Lymph Nodes

August 27th 2024

Jean-Marc Classe, MD, PhD, discusses omitting lymphadenectomy in patients with advanced epithelial ovarian cancer.

Bispecific Antibody De-Escalation: Varying Dosing Strategies Aim to Improve Safety, Maintain Efficacy in R/R Myeloma

August 27th 2024

Rahul Banerjee MD, FACP, discusses various dosing strategies and schedules for bispecific antibodies in multiple myeloma.

BRIA-ABC Trial Explores Novel Post-ADC Strategy for Metastatic Breast Cancer

August 27th 2024

Saranya Chumsri, MD, and Adam M. Brufsky, MD, PhD, discuss the evaluation of Bria-IMT plus a checkpoint inhibitor in metastatic breast cancer

Expert Teams, Exceptional Outcomes: AHN Cancer Institute’s Disease Site Centers Drive Innovation

August 27th 2024

AHN Cancer Institute’s Centers of Excellence unite teams of experts to provide patients with high-quality, collaborative care in a supportive environment.

Crovalimab Earns Approval in Europe for Paroxysmal Nocturnal Hemoglobinuria

August 27th 2024

The European Commission has approved crovalimab for adult and pediatric patients with paroxysmal nocturnal hemoglobinuria.

Amivantamab Plus Chemotherapy Wins EU Approval for Pretreated EGFR+ Advanced NSCLC

August 27th 2024

Amivantamab plus chemotherapy has received European approval for EGFR-mutant non–small cell lung cancer that progressed on an EGFR TKI.

64Cu-SAR-bisPSMA Earns FDA Fast Track Designation for PET Imaging in Prostate Cancer

August 27th 2024

The FDA has granted fast track designation to 64Cu-SAR-bisPSMA for PET imaging of PSMA-positive prostate cancer lesions.